Logo path
Novel Inhalation Technology

Softhale is developing pharmaceutical inhalation products for major respiratory markets in the U.S., Europe, and Asia. These products are based upon a differentiated inhalation delivery technology called SOFTHALER®. This device is a next-generation Soft Mist Inhaler (SMI), which offers a platform technology for delivering various drugs to the lungs. As well as generic products, innovative products are also targeted.

PM Equity Partner has exited its investment in Softhale.

Website url